Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

by B2i | May 14, 2024 | Press Releases

Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against...

Dyadic to Attend Industry and Investor Events in May

by B2i | May 8, 2024 | Press Releases

JUPITER, Fla., May 08, 2024 — Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein...

Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024

by B2i | Apr 30, 2024 | Press Releases

JUPITER, Fla., April 30, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...

Dyadic Reports 2023 Full Year Results and Recent Company Progress

by B2i | Mar 28, 2024 | Press Releases

Closed a $6.0 million convertible note in a private placement, with a conversion price of $1.79 and no warrantsReported positive topline data from First-In-Human Phase 1 trial demonstrated clinical safety and antibody response for DYAI-100 a recombinant protein...

Dyadic Announces Change in Board and Management Leadership Roles

by B2i | Mar 28, 2024 | Press Releases

JUPITER, Fla., March 28, 2024 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of...